USFDA lifts import alert from Sun Pharma’s Mohali plant


Sun Pharma said the US FDA will lift the import alert imposed on the Mohali (Punjab) manufacturing facility and remove the facility from official action initiated (OAI) status. This proposed action will clear the path for Sun Pharma to supply approved products from the Mohali facility to the US market, subject to normal US FDA regulatory requirements, the company said in a BSE filing on Tuesday. Sun Pharma scrip jumped by over 5% on the BSE.sun-pharmaceutical-industries

The Mohali facility was inherited by Sun Pharma as part of its acquisition of Ranbaxy in 2015. The US FDA had taken action against the facility in 2013 when it ordered it to be fully subject to Ranbaxy’s Consent Decree of Permanent Injunction. Certain conditions of the consent decree will continue to be applicable to the Mohali facility, the company added.

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Most Popular

To Top